162 related articles for article (PubMed ID: 8673528)
1. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
[TBL] [Abstract][Full Text] [Related]
2. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
[TBL] [Abstract][Full Text] [Related]
3. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
Rathbun RC; Martin ES
Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
[TBL] [Abstract][Full Text] [Related]
4. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
Spruance SL; Pavia AT; Peterson D; Berry A; Pollard R; Patterson TF; Frank I; Remick SC; Thompson M; MacArthur RD; Morey GE; Ramirez-Ronda CH; Bernstein BM; Sweet DE; Crane L; Peterson EA; Pachucki CT; Green SL; Brand J; Rios A; Dunkle LM; Cross A; Brown MJ; Ingraham P; Gugliotti R; Schindzielorz AH; Smaldone L
Ann Intern Med; 1994 Mar; 120(5):360-8. PubMed ID: 7905722
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.
Vella S; Floridia M; Dally LG; Tomino C; Fragola V; Weimer LE; Milazzo F; Mazzotta F; Moroni M; Pastore G; Scalise G; Sinicco A; Ortona L; De Rienzo B; Dianzani F
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):462-9. PubMed ID: 8757422
[TBL] [Abstract][Full Text] [Related]
6. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D
N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040
[TBL] [Abstract][Full Text] [Related]
7. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
[TBL] [Abstract][Full Text] [Related]
8. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
Dolin R; Amato DA; Fischl MA; Pettinelli C; Beltangady M; Liou SH; Brown MJ; Cross AP; Hirsch MS; Hardy WD
Arch Intern Med; 1995 May; 155(9):961-74. PubMed ID: 7726705
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
Kahn JO; Lagakos SW; Richman DD; Cross A; Pettinelli C; Liou SH; Brown M; Volberding PA; Crumpacker CS; Beall G
N Engl J Med; 1992 Aug; 327(9):581-7. PubMed ID: 1353607
[TBL] [Abstract][Full Text] [Related]
10. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
Montaner JS; Schechter MT; Rachlis A; Gill J; Beaulieu R; Tsoukas C; Raboud J; Cameron B; Salomon H; Dunkle L; Smaldone L; Wainberg MA
Ann Intern Med; 1995 Oct; 123(8):561-71. PubMed ID: 7677296
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
Floridia M; Vella S; Seeber AC; Tomino C; Fragola V; Weimer LE; Ricciardulli D; Milazzo F; Gritti FM; Mazzotta F; Ranieri S; Chiodo F; Moroni M; Cargnel A; Bassetti D; Giannini V; Cremoni L; Concia E; Sinicco A; Carosi G; Alberici F; Dianzani F
J Infect Dis; 1997 Feb; 175(2):255-64. PubMed ID: 9203645
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
Mauss S; Adams O; Willers R; Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):469-77. PubMed ID: 8605592
[TBL] [Abstract][Full Text] [Related]
14. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
D'Aquila RT; Hughes MD; Johnson VA; Fischl MA; Sommadossi JP; Liou SH; Timpone J; Myers M; Basgoz N; Niu M; Hirsch MS
Ann Intern Med; 1996 Jun; 124(12):1019-30. PubMed ID: 8633815
[TBL] [Abstract][Full Text] [Related]
15. Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.
d'Arminio Monforte A; Musicco M; Galli M; Paga C; La Regina A; Lazzarin A; Angarano G; Milazzo F; Gritti F; Arlotti M; Mazzotta F; Visco G; Aiuti F; Moroni M
Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):135-42. PubMed ID: 9105840
[TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
Henry K; Erice A; Tierney C; Balfour HH; Fischl MA; Kmack A; Liou SH; Kenton A; Hirsch MS; Phair J; Martinez A; Kahn JO
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):339-49. PubMed ID: 9833742
[TBL] [Abstract][Full Text] [Related]
17. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).
Moyle GJ; Nelson MR; Hawkins D; Gazzard BG
Q J Med; 1993 Mar; 86(3):155-63. PubMed ID: 8387218
[TBL] [Abstract][Full Text] [Related]
18. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
[TBL] [Abstract][Full Text] [Related]
19. A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
Gatell JM; Leal M; Mallolas J; Vidal C; Pumarola T; Parra R; Padró S; Caruz A; Falgueras T; Rey C; Sánchez-Quijano A; Torres Y; Lissen E; Jiménez de Anta MT; Soriano E
Antivir Ther; 1996 Apr; 1(2):105-12. PubMed ID: 11321180
[TBL] [Abstract][Full Text] [Related]
20. AIDS: Part II.
Kessler HA; Bick JA; Pottage JC; Benson CA
Dis Mon; 1992 Oct; 38(10):691-764. PubMed ID: 1396036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
